Hypertrophic cardiomyopathy: Difference between revisions

No edit summary
No edit summary
Line 14: Line 14:
*Syncope, chest pain, dyspnea
*Syncope, chest pain, dyspnea
*Symptoms made worse by exertion
*Symptoms made worse by exertion
**Inc ventricular contraction further narrows outflow


==Differential Diagnosis==
==Differential Diagnosis==

Revision as of 03:08, 19 May 2016

Background

  • Genetically-linked (AD) hypertrophy of cardiac muscle - can but does not always cause outflow obstruction
  • Diastolic heart failure
    • Abnormal LV function due to decreased compliance
  • Historically, obstructive forms known as:
    • Idiopathic hypertrophic subaortic stenosis (IHSS)
    • Asymmetric septal hypertrophy (ASH)
    • Hypertrophic obstructive cardiomyopathy (HOCM)
  • Yamaguchi syndrome, an atypical HCOM, in which only 1% are non-Japanese
HOCM

Clinical Features

  • Syncope, chest pain, dyspnea
  • Symptoms made worse by exertion
    • Inc ventricular contraction further narrows outflow

Differential Diagnosis

Cardiomyopathy

Chest pain

Critical

Emergent

Nonemergent

Diagnosis

  • Sx: Syncope or sudden death most common
    • Also exertional dyspnea, chest pain, syncope, dizziness, palpitations, or CHF
  • Systolic murmur that increases w/ maneuvers that decrease preload (e.g. valsalva, transitioning from squatting to standing, etc.).
  • EKG
    • Nonspecific/normal.
    • Or, high voltage/LVH, deep narrow Q waves in 1, avL, V5, V6 = "daggers of death"

Work-Up

  • EKG
    • May show signs of:
      • LVH
      • "Needle-like" Q waves
  • CXR
  • ECHO

Management

  • Definitive treatment is myomectomy

Decompensated

  • Consider primary insult, which usually is preload issue (fluid depletion, bleed, etc.)
  • If decompensated presents as hypotensive CHF
    • Preserve preload
      • Careful hydration
      • Avoid high airway pressure if intubate
    • Limit tachycardia
      • Beta blockers
    • Avoid vasodilators (no nitrates)
    • Maintain sinus rythm (i.e. cardiovert A. fib)
    • Increase afterload (hypotensive only)
      • Phenylephrine, max dose range depending on source
        • Start at 100 mcg/min (~1.5 mcg/kg/min for average adult)
        • Range usually 0.5 - 6.0 mcg/kg/min, with efficacy minimal beyond 6 mcg/kg/min)[1]
        • Max phenylephrine infusion before other pressors
        • Fix acid-base disorder as acidosis may prevent pressor efficacy
        • Consider maxing vasopressin next
          • Pressor effects more preserved in hypoxia and acidosis[2]
          • Preferred over pressors with beta agonism
      • Push dose pressor while waiting for IV drip:
        • Place 1mL of 10mg/mL phenylephrine in 100mL NS
        • Final concentration 100mcg/mL
        • Use 1-2mL q2-5min (100-200mcg) in 10mL syringe
        • Onset 1min; duration 20min

Pharmacologic Management

  • Per Amer Coll of Cardiology 2011 recommendations[3]
  • Class I
    • BBs for angina or dyspnea in adults in HCM regardless of obstructive physiology - use with caution in sinus brady or conduction abnormality
    • Titrate BB dose to symptoms, may increase BB dose to resting HR to 60 bpm
    • PO verapamil titrated up to 480 mg/d if pt unresponsive or cannot tolerate BBs - caution in advanced HF, hypotension, sinus brady, high LVOT gradients
    • IV phenylephrine for acute hypotension unresponsive to fluids
  • Class IIa
    • Reasonable to add disopyramide with BB or verapamil if unresponsive to BB or CCB alone in obstructive HCM
    • Reasonable to add oral diuretics in nonobstructive HCM when symptoms persist despite BB or CCB
  • Class III (harm)
    • Avoid nifedipine and other dihydropyridine CCB
    • Avoid digitalis
    • Avoid disopyramide alone w/o BB or CCB
    • Avoid positive inotropic vasopressors (dopamine, dobutamine, norepi, epi)

Disposition

  • Admit

See Also

References

  1. Global RPH in reference to Micromedex. 12/2014. http://www.globalrph.com/phenylephrine_dilution.htm
  2. Overgaard CB and Dzavik V. Contemporary Reviews in Cardiovascular Medicine: Inotropes and Vasopressors - Review of Physiology and Clinical Use in Cardiovascular Disease. Circulation. 2008; 118: 1047-1056.
  3. American College of Cardiology. 2011. http://content.onlinejacc.org/article.aspx?articleid=1147838